Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL22409695 | 0.99 | MGLL (0.69) | MGLLFAAH | |
| SCHEMBL29446985 | 0.85 | MGLL (0.56) | MGLLFAAH | |
| SCHEMBL20168397 | 0.85 | MGLL (0.56) | MGLLFAAH | |
| SCHEMBL25802776 | 0.85 | MGLL (0.51) | MGLL | |
| SCHEMBL20182525 | 0.83 | MGLL (0.77) | MGLL | |
| SCHEMBL20166493 | 0.83 | MGLL (1.00) | MGLL | |
| Hydrochloric Acid SCHEMBL22409693 | 0.82 | MGLL (0.69) | MGLLFAAH | |
| SCHEMBL20182411 | 0.82 | MGLL (0.69) | MGLLFAAH | |
| Hydrochloric Acid SCHEMBL29446983 | 0.82 | MGLL (0.69) | MGLLFAAH | |
| SCHEMBL22350712 | 0.80 | MGLL (0.45) | MGLLFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3541820-B1 | MAGL INHIBITORS | H LUNDBECK AS (DK) | 2023-07-05 | — | — | EP | disclosed |
| US-11691975-B2 | MAGL inhibitors | H. LUNDBECKA/S (DK) | 2023-07-04 | — | — | US | disclosed |
| US-20220135563-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2022-05-05 | — | — | US | disclosed |
| US-11059822-B2 | MAGL inhibitors | H. LUNDBECK A/S (DK) | 2021-07-13 | — | — | US | disclosed |
| US-20200291023-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2020-09-17 | — | — | US | disclosed |
| EP-3541820-A1 | MAGL INHIBITORS | Abide Therapeutics, Inc. (US) | 2019-09-25 | — | — | EP | disclosed |
| WO-2018093949-A1 | MAGL INHIBITORS | ABIDE THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | WO | disclosed |
| WO-2018093949-A1 | MAGL INHIBITORS | ABIDE THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11059822-B2 | MAGL inhibitors | MAG, MAGI3, MGLL | MGLL 3/4885FAAH 29/4885 |
| US-20220135563-A1 | MAGL INHIBITORS | MAG, MAGI3, MGLL | MGLL 3/4885FAAH 29/4885 |
| US-20200291023-A1 | MAGL INHIBITORS | MAG, MAGI3, MGLL | MGLL 3/4885FAAH 29/4885 |
| US-11691975-B2 | MAGL inhibitors | MAG, MAGI3, MGLL | MGLL 3/4885FAAH 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.